True precision medicine through single-cell science
Scailyte has established a data-driven biomarker discovery platform that leverages unique expertise in single-cell data analysis and artificial intelligence. We are utilizing this platform to discover a new class of biomarkers, which are defined by the molecular profiles of disease-associated cells. This phenotypic approach to biomarker discovery is radically new and directly related to the biology of a disease, which maximizes the success rate for discovering sensitive and robust biomarkers.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 12, 2020 | Seed | Fr600K | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Verve Ventures | — | Seed |